PCYT2 CRISPR/Cas9 KO Plasmid (h): sc-416514
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PCYT2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PCYT2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PCYT2 CRISPR/Cas9 KO Plasmid (h) | sc-416514 | 20 µg | $397.00 |
Overview
PCYT2 encodes CTP:phosphoethanolamine cytidylyltransferase, a rate-limiting enzyme in the Kennedy pathway that generates CDP-ethanolamine for phosphatidylethanolamine (PE) biosynthesis. By controlling PE availability, PCYT2 influences membrane biogenesis, ER and mitochondrial membrane composition, lipid droplet dynamics, and autophagy-related membrane remodeling. PCYT2-dependent phospholipid homeostasis intersects with cellular energy balance and stress signaling pathways that respond to altered membrane lipid composition. Genetic disruption or reduced activity of PCYT2 has been linked to inherited neuromuscular and neurodevelopmental phenotypes, supporting its relevance for modeling lipid metabolism–associated disease mechanisms in human cells.
PCYT2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PCYT2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PCYT2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PCYT2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PCYT2 protein expression.
This CRISPR knockout system enables efficient generation of PCYT2-deficient cell models for investigation of PCYT2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PCYT2 exon(s) critical for PCYT2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PCYT2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PCYT2 CRISPR/Cas9 KO Plasmid (h) and PCYT2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PCYT2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PCYT2 HDR Plasmid (h) and PCYT2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PCYT2 homology arms to support homology-directed repair at defined PCYT2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.